Intrexon Corporation (NYSE:XON) Shares Shorted Decreased By 4.94%

June 29, 2018 - By Susanne Funderburg

Intrexon Corporation (NYSE:XON) Corporate Logo

During 2018 Q1 the big money sentiment increased to 1.78. That’s change of 0.40, from 2017Q4’s 1.38. 20 investors sold all, 26 reduced holdings as Intrexon Corporation ratio increased. 58 rose positions while 24 funds acquired positions. Funds hold 106.32 million shares thus 10.20% more from 2017Q4’s 96.48 million shares.
Shelton Cap Management stated it has 0.01% of its capital in Intrexon Corporation (NYSE:XON). Utah Retirement Sys owns 11,900 shs for 0% of their capital. Farr Miller Washington Llc Dc owns 64,086 shs. Alliancebernstein Limited Partnership has invested 0% in Intrexon Corporation (NYSE:XON). Peloton Wealth Strategists holds 0.41% in Intrexon Corporation (NYSE:XON) or 35,400 shs. The New York-based Opus Point Prtnrs Management Limited Co has invested 0.56% in Intrexon Corporation (NYSE:XON). Raymond James And Assocs holds 0% of its capital in Intrexon Corporation (NYSE:XON) for 33,917 shs. San Francisco Sentry Invest Gp (Ca) holds 100 shs. Nomura Holdings owns 11,949 shs for 0% of their capital. Bank Of Montreal Can holds 0% or 98,893 shs in its capital. The Massachusetts-based State Street has invested 0% in Intrexon Corporation (NYSE:XON). Bancorp Of America Corp De stated it has 562,159 shs or 0% of all its holdings. Michael And Susan Dell Foundation holds 10.39% of its capital in Intrexon Corporation (NYSE:XON) for 432,878 shs. Cambridge Advsrs Incorporated holds 0.01% or 71,155 shs. Hightower Advisors Ltd Liability Corporation holds 39,833 shs or 0.01% of its capital.

Intrexon Corporation registered $12.50 million net activity with 1 insider purchase and 0 insider sales since January 19, 2018.

It was registered a decrease on Intrexon Corporation (NYSE:XON)’s shorted shares with 4.94%. It was published in June by FINRA the 22.69M shorted shares on XON. Previously was reported down change of 4.94% from 23.87M shares. Intrexon Corporation (NYSE:XON) has 1.21M shares average volume. It’ll cost 19 days for XON to restore its previous position. Intrexon Corporation float short is 46.14%.

The stock increased 9.72% or $1.3 during the last trading session, touching $14.67.Intrexon Corporation is downtrending after having declined 29.17% since June 29, 2017. XON has 8.54 million volume or 560.36% up from normal. XON underperformed by 41.74% the S&P 500.

Intrexon Corporation operates in the synthetic biology field in the United States.The company has $1.90 billion market cap. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components.Last it reported negative earnings. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics platform.

Intrexon Corporation (NYSE:XON) Ratings Coverage

In total 3 analysts cover Intrexon (NYSE:XON). “Buy” rating has 1, “Sell” are 0, while 2 are “Hold”. (NYSE:XON) has 33% bullish analysts. 3 are the (NYSE:XON)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc. In Friday, March 2 report Northland Capital maintained it with “Buy” rating and $17.0 target. On Monday, March 5 the rating was maintained by JP Morgan with “Neutral”. On Friday, March 2 the rating was maintained by Bank of America with “Neutral”.

For more Intrexon Corporation (NYSE:XON) news announced briefly go to:,,, or The titles are as follows: “After-Hours Stock Movers 06/27: (EDGE) (ZSAN) (MSG) Higher; (PIR) (BBBY) (XON) Lower (more…)” announced on June 27, 2018, “CenturyLink’s Yield Is A Red Flag – Cramer’s Lightning Round (6/18/18)” on June 19, 2018, “Intrexon’s (XON) Oxitec Partners with Bill & Melinda Gates Foundation for Malaria” with a publish date: June 19, 2018, “Intrexon (XON) Prices 7.48M Share Common Offering at $13.37/Sh” and the last “Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19 …” with publication date: June 18, 2018.

Intrexon Corporation (NYSE:XON) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.